The safety and side effects of monoclonal antibodies (original) (raw)

• Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975). The original manuscript describing the breakthrough of hybridoma technology and the production of mAbs.
  Article PubMed Google Scholar
• Strebhardt, K. & Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Rev. Cancer 8, 473–480 (2008).
  Article CAS Google Scholar
• Dubel, S. (ed.) Handbook of Therapeutic Antibodies. Volume I: Technologies, Volume II: Emerging Developments, Volume III: Approved Therapeutics (Wiley, Weinhem, 2007). A comprehensive three volume multiple-author text on therapeutic antibodies.
  Book Google Scholar
• Lonberg, N. Human antibodies from transgenic animals. Nature Biotech. 23, 1117–1125 (2005).
  Article CAS Google Scholar
• Reichert, J. M., Rosensweig, C. J., Faden, L. B. & Dewitz, M. C. Monoclonal antibody successes in the clinic. Nature Biotech. 23, 1073–1078 (2005).
  Article CAS Google Scholar
• Waldmann, T. A. Immunotherapy: past, present and future. Nature Med. 9, 269–277 (2003).
  Article CAS PubMed Google Scholar
• Reichert, J. M. & Dewitz, M. C. Anti-infective monoclonal antibodies: perils and promise of development. Nature Rev. Drug Discov. 5, 191–195 (2006).
  Article CAS Google Scholar
• Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nature Rev. Drug Discov. 7, 21–39 (2008).
  Article CAS Google Scholar
• Waldmann, H. & Hale, G. CAMPATH: from concept to clinic. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360, 1707–1711 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Nissim, A. & Chernajovsky, Y. Historical development of monoclonal antibody therapeutics. Handb. Exp. Pharmacol. 181, 3–18 (2008).
  Article CAS Google Scholar
• Presta, L. G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460–470 (2008).
  Article CAS PubMed Google Scholar
• Hale, G. Therapeutic antibodies-delivering the promise? Adv. Drug Deliv. Rev 58, 633–639 (2006).
  Article CAS PubMed Google Scholar
• Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244–279 (2008).
  Article CAS PubMed Google Scholar
• Giezen, T. J. et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300, 1887–1896 (2008). An important review of regulatory actions regarding the safety of biologics.
  Article CAS PubMed Google Scholar
• Zink, A. et al. European biologicals registers: methodology, selected results and perspectives. Ann. Rheum. Dis. 68, 1240–1246 (2009).
  Article CAS PubMed Google Scholar
• Lutterotti, A. & Martin, R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7, 538–547 (2008).
  Article CAS PubMed Google Scholar
• Yeung, Y. A. et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol. 182, 7663–7671 (2009).
  Article CAS PubMed Google Scholar
• Chang, T. W. Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Allergy Asthma Proc. 27, S7–S14 (2006).
  CAS PubMed Google Scholar
• Hassan, M. S., bedi-Valugerdi, M., Lefranc, G., Hammarstrom, L. & Smith, C. I. Biological half-life of normal and truncated human IgG3 in SCID mice. Eur. J. Immunol. 21, 1319–1322 (1991).
  Article CAS PubMed Google Scholar
• Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30, 356–362 (2009).
  Article CAS PubMed Google Scholar
• Holland, M. et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin. Exp. Immunol. 138, 183–192 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554–1557 (2007).
  Article CAS Google Scholar
• Tabrizi, M. A. & Roskos, L. K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12, 540–547 (2007).
  Article CAS PubMed Google Scholar
• Cavagnaro, J. A. (ed.) Preclinical Safety Evaluation of Biopharmaceuticals: A Science Based Approach to Facilitating Clinical Trials (Wiley, London, 2008). A recent book on preclinical safety testing of biopharmaceuticals.
  Book Google Scholar
• Longstaff, C., Whitton, C. M., Stebbings, R. & Gray, E. How do we assure the quality of biological medicines? Drug Discov. Today 14, 50–55 (2009).
  Article CAS PubMed Google Scholar
• Loisel, S. et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit. Rev. Oncol. Hematol. 62, 34–42 (2007).
  Article PubMed Google Scholar
• Chapman, K., Pullen, N., Graham, M. & Ragan, I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Rev. Drug Discov. 6, 120–126 (2007).
  Article CAS Google Scholar
• Presta, L. G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58, 640–656 (2006).
  Article CAS PubMed Google Scholar
• Chung, C. H. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13, 725–732 (2008).
  Article CAS PubMed Google Scholar
• Klastersky, J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr. Opin. Oncol. 18, 316–320 (2006).
  Article CAS PubMed Google Scholar
• Kang, S. P. & Saif, M. W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer — identification, prevention, and management. J. Support. Oncol. 5, 451–457 (2007).
  CAS PubMed Google Scholar
• Lenz, H. J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12, 601–609 (2007).
  Article CAS PubMed Google Scholar
• Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).
  Article CAS PubMed Google Scholar
• Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358, 1109–1117 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Poole, J. A., Matangkasombut, P. & Rosenwasser, L. J. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J. Allergy Clin. Immunol. 115, S376–S385 (2005).
  Article PubMed Google Scholar
• Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nature Rev. Immunol. 8, 205–217 (2008).
  Article CAS Google Scholar
• Cox, L. et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120, 1373–1377 (2007).
  Article CAS PubMed Google Scholar
• Corren, J. et al. Safety and tolerability of omalizumab. Clin. Exp. Allergy 39, 788–797 (2009).
  Article CAS PubMed Google Scholar
• Cox, L. S. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin. Immunol. 5, 4 (2009).
  Article PubMed PubMed Central Google Scholar
• Limb, S. L., Starke, P. R., Lee, C. E. & Chowdhury, B. A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 120, 1378–1381 (2007).
  Article CAS PubMed Google Scholar
• Carter, P. Improving the efficacy of antibody-based cancer therapies. Naure Rev. Cancer 1, 118–129 (2001).
  Article CAS Google Scholar
• Loertscher, R. The utility of monoclonal antibody therapy in renal transplantation. Transplant. Proc. 34, 797–800 (2002).
  Article CAS PubMed Google Scholar
• Gaston, R. S. et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int. 39, 141–148 (1991).
  Article CAS PubMed Google Scholar
• Kuus-Reichel, K. et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1, 365–372 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Mascelli, M. A. et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J. Clin. Pharmacol. 47, 553–565 (2007).
  Article CAS PubMed Google Scholar
• Carter, P. J. Potent antibody therapeutics by design. Nature Rev. Immunol. 6, 343–357 (2006).
  Article CAS Google Scholar
• Azinovic, I. et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother. 55, 1451–1458 (2006).
  Article CAS PubMed Google Scholar
• Clark, M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today 21, 397–402 (2000).
  Article CAS PubMed Google Scholar
• Ransohoff, R. M. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356, 2622–2629 (2007).
  Article CAS PubMed Google Scholar
• Cohen, B. A., Oger, J., Gagnon, A. & Giovannoni, G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J. Neurol. Sci. 275, 7–17 (2008).
  Article CAS PubMed Google Scholar
• Schellekens, H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 (Suppl. 6), vi3–vi9 (2005).
  Article CAS PubMed Google Scholar
• Todd, D. J. & Helfgott, S. M. Serum sickness following treatment with rituximab. J. Rheumatol. 34, 430–433 (2007).
  PubMed Google Scholar
• Schellekens, H., Crommein, D. & Jiskoot, W. in Handbook of Therapeutic Antibodies Vol. 1 Ch. 11 (ed. Dubel, S.) (Wiley, Weinheim, 2007).
  Google Scholar
• Shankar, G., Shores, E., Wagner, C. & Mire-Sluis, A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24, 274–280 (2006).
  Article CAS PubMed Google Scholar
• Aarden, L., Ruuls, S. R. & Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20, 431–435 (2008).
  Article CAS PubMed Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006. EMA website [online], (2007).
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Doc. Ref. EMEA/CHMP/BMWP/114720/2009. EMA website [online], (2009). Recent EMA guidelines on immunogenicity testing of mAbs.
• Coiffier, B., Altman, A., Pui, C. H., Younes, A. & Cairo, M. S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J. Clin. Oncol. 26, 2767–2778 (2008).
  Article CAS PubMed Google Scholar
• Tosi, P. et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 93, 1877–1185 (2008).
  Article PubMed Google Scholar
• Otrock, Z. K., Hatoum, H. A. & Salem, Z. M. Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma. Intern. Emerg. Med. 3, 161–163 (2008).
  Article PubMed Google Scholar
• Feusner, J. H., Ritchey, A. K., Cohn, S. L. & Billett, A. L. Management of tumor lysis syndrome: need for evidence-based guidelines. J. Clin. Oncol. 26, 5657–5658 (2008).
  Article PubMed Google Scholar
• Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Rev. Rheumatol. 5, 578–582 (2009).
  Article CAS Google Scholar
• Feldmann, M. & Maini, S. R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 223, 7–19 (2008).
  Article CAS PubMed Google Scholar
• Moss, M. L., Sklair-Tavron, L. & Nudelman, R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 4, 300–309 (2008).
  Article CAS Google Scholar
• Keane, J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44, 714–720 (2005).
  Article CAS PubMed Google Scholar
• Askling, J. et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52, 1986–1992 (2005).
  Article CAS PubMed Google Scholar
• Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).
  Article CAS PubMed Google Scholar
• Schneeweiss, S. et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 56, 1754–1764 (2007).
  Article CAS PubMed Google Scholar
• Theis, V. S. & Rhodes, J. M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 27, 19–30 (2008).
  Article CAS PubMed Google Scholar
• Colombel, J. F. et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126, 19–31 (2004).
  Article CAS PubMed Google Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60, 800–805 (2005).
• Major, E. O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35–47 (2010).
  Article CAS PubMed Google Scholar
• Carson, K. R. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 10, 816–824 (2009).
  Article CAS PubMed Google Scholar
• Lopez-Diego, R. S. & Weiner, H. L. Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary. Nature Rev. Drug Discov. 7, 909–925 (2008).
  Article CAS Google Scholar
• Sadiq, S. A., Puccio, L. M. & Brydon, E. W. JCV detection in multiple sclerosis patients treated with natalizumab. J. Neurol. 7 Jan 2010 (doi:10.1007/s00415-009-5444-4).
  Article CAS PubMed Google Scholar
• Major, E. O. Reemergence of PML in natalizumab-treated patients — new cases, same concerns. N. Engl. J. Med. 361, 1041–1043 (2009).
  Article CAS PubMed Google Scholar
• Kleinschmidt-DeMasters, B. K. & Tyler, K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353, 369–374 (2005).
  Article CAS PubMed Google Scholar
• Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381 (2005).
  Article CAS PubMed Google Scholar
• Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362–368 (2005). References 77–79 are the original descriptions of cases of PML with natalizumab.
  Article CAS PubMed Google Scholar
• Wenning, W. et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 361, 1075–1080 (2009).
  Article CAS PubMed Google Scholar
• Linda, H. et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361, 1081–1087 (2009). References 80 and 81 are recent descriptions of cases of PML with natalizumab.
  Article CAS PubMed Google Scholar
• Yousry, T. A. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924–933 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kappos, L. et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 6, 431–441 (2007).
  Article PubMed Google Scholar
• Clifford, D. B. Natalizumab and PML: a risky business? Gut 57, 1347–1349 (2008).
  Article PubMed Google Scholar
• Landry, M. L., Eid, T., Bannykh, S. & Major, E. False negative PCR despite high levels of JC virus DNA in spinal fluid: implications for diagnostic testing. J. Clin. Virol. 43, 247–249 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Y. et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361, 1067–1074 (2009).Documentation that reactivation of JCV occurs commonly with natalizumab therapy in multiple sclerosis.
  Article CAS PubMed PubMed Central Google Scholar
• Delbue, S., Tremolada, S. & Ferrante, P. Application of molecular tools for the diagnosis of central nervous system infections. Neurol. Sci. 29 (Suppl. 2), 283–285 (2008).
  Article Google Scholar
• Molloy, E. S. & Calabrese, L. H. Therapy: targeted but not trouble-free: efalizumab and PML. Nature Rev. Rheumatol. 5, 418–419 (2009).
  Article CAS Google Scholar
• Bonig, H., Wundes, A., Chang, K. H., Lucas, S. & Papayannopoulou, T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111, 3439–3441 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zohren, F. et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111, 3893–3895 (2008).
  Article CAS PubMed Google Scholar
• Aksoy, S. et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 48, 1307–1312 (2007).
  Article CAS PubMed Google Scholar
• Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834–4840 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Aster, R. H. & Bougie, D. W. Drug-induced immune thrombocytopenia. N. Engl. J. Med. 357, 580–587 (2007).
  Article PubMed Google Scholar
• Topol, E. J., Byzova, T. V. & Plow, E. F. Platelet GPIIb-IIIa blockers. Lancet 353, 227–231 (1999).
  Article CAS PubMed Google Scholar
• Tcheng, J. E. et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104, 870–875 (2001).
  Article CAS PubMed Google Scholar
• Topol, E. J. et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 113, 1–6 (2002).
  Article CAS PubMed Google Scholar
• Tamhane, U. U. & Gurm, H. S. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin. Drug Saf. 7, 809–819 (2008).
  Article CAS PubMed Google Scholar
• Curtis, B. R., Divgi, A., Garritty, M. & Aster, R. H. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J. Thromb. Haemost. 2, 985–992 (2004).
  Article CAS PubMed Google Scholar
• Curtis, B. R., Swyers, J., Divgi, A., McFarland, J. G. & Aster, R. H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99, 2054–2059 (2002).
  Article CAS PubMed Google Scholar
• McCorry, R. B. & Johnston, P. Fatal delayed thrombocytopenia following abciximab therapy. J. Invasive Cardiol. 18, E173–E174 (2006).
  PubMed Google Scholar
• Mukherjee, D. & Roffi, M. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role? J. Interv. Cardiol. 21, 118–121 (2008).
  Article PubMed Google Scholar
• Cox, A. L. et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332–3342 (2005).
  Article CAS PubMed Google Scholar
• Lorenzi, A. R. et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum. 58, 370–375 (2008).
  Article PubMed Google Scholar
• Chakrabarti, S. et al. T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br. J. Haematol. 121, 109–118 (2003).
  Article PubMed Google Scholar
• Hale, G. et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 26, 69–76 (2000).
  Article CAS PubMed Google Scholar
• Lin, T. S. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clin. Lymphoma Myeloma. 8 (Suppl. 4), 137–143 (2008).
  Article CAS Google Scholar
• Watson, C. J. et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation — efficacy and safety at five years. Am. J. Transplant. 5, 1347–1353 (2005).
  Article CAS PubMed Google Scholar
• Coles, A. J. et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).
  Article PubMed Google Scholar
• Hauser, S. L. Multiple lessons for multiple sclerosis. N. Engl. J. Med. 359, 1838–1841 (2008).
  Article CAS PubMed Google Scholar
• Haider, I. & Cahill, M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 9, 409–411 (2004).
  Article CAS PubMed Google Scholar
• Gibbs, S. D., Westerman, D. A., McCormack, C., Seymour, J. F. & Miles, P. H. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br. J. Haematol. 130, 87–91 (2005).
  Article CAS PubMed Google Scholar
• Patel, V. L., Schwartz, J. & Bussel, J. B. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br. J. Haematol. 141, 545–548 (2008).
  Article CAS PubMed Google Scholar
• Koyama, I. et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77, 460–462 (2004).
  Article CAS PubMed Google Scholar
• Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H. & Cosimi, A. B. Letters to the Editor: Thromboembolic complications after treatment with monoclonal antibody against CD49 ligand. Nature Med. 6, 114 (2000).
  Article CAS PubMed Google Scholar
• Kirk, A. D. & Harlan, D. M. Letters to the Editor: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Med. 6, 114 (2000).
  Article CAS Google Scholar
• Mirabet, M., Barrabes, J. A., Quiroga, A. & Garcia-Dorado, D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol. Immunol. 45, 937–944 (2008).
  Article CAS PubMed Google Scholar
• Langer, F. et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb. Haemost. 93, 1137–1146 (2005).
  Article CAS PubMed Google Scholar
• Scappaticci, F. A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99, 1232–1239 (2007).
  Article PubMed Google Scholar
• Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X. & Wu, S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300, 2277–2285 (2008).
  Article CAS PubMed Google Scholar
• Mongey, A. B. & Hess, E. V. Drug insight: autoimmune effects of medications — what's new? Nature Clin. Pract. Rheumatol. 4, 136–144 (2008).
  Article CAS Google Scholar
• Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 86, 242–251 (2007).
  Article PubMed Google Scholar
• Haraoui, B. & Keystone, E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr. Opin. Rheumatol. 18, 96–100 (2006).
  Article PubMed Google Scholar
• Coles, A. J. et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691–1695 (1999).
  Article CAS PubMed Google Scholar
• Fong, L. & Small, E. J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275–5283 (2008).
  Article CAS PubMed Google Scholar
• Maker, A. V., Attia, P. & Rosenberg, S. A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746–7754 (2005).
  Article CAS PubMed Google Scholar
• Peggs, K. S., Quezada, S. A., Korman, A. J. & Allison, J. P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206–213 (2006).
  Article CAS PubMed Google Scholar
• Weber, J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864–872 (2007).
  Article CAS PubMed Google Scholar
• Kaufman, H. L. & Wolchok, J. D. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J. Clin. Oncol. 24, 2230–2232 (2006).
  Article CAS PubMed Google Scholar
• Askling, J. & Bongartz, T. Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 334–339 (2008).
  Article CAS PubMed Google Scholar
• Scott, D. L. & Kingsley, G. H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355, 704–712 (2006).
  Article CAS PubMed Google Scholar
• Dixon, W. & Silman, A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz. et al. Arthritis Res. Ther. 8, 111 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Askling, J. et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1421–1426 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Setoguchi, S. et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2757–2764 (2006).
  Article CAS PubMed Google Scholar
• Biancone, L., Calabrese, E., Petruzziello, C. & Pallone, F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nature Clin. Pract. Gastroenterol. Hepatol. 4, 78–91 (2007).
  Article CAS Google Scholar
• Rennard, S. I. et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 926–934 (2007).
  Article CAS PubMed Google Scholar
• Rosh, J. R., Gross, T., Mamula, P., Griffiths, A. & Hyams, J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13, 1024–1030 (2007).
  Article PubMed Google Scholar
• Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
  Article CAS PubMed Google Scholar
• Sandborn, W. J. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135, 1442–1447 (2008).
  Article PubMed Google Scholar
• Segal, B. M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796–804 (2008).
  Article CAS PubMed Google Scholar
• Weiss, J. M., Subleski, J. J., Wigginton, J. M. & Wiltrout, R. H. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert. Opin. Biol. Ther. 7, 1705–1721 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461–465 (2006).
  Article CAS PubMed Google Scholar
• Knox, S. J. et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2, 457–470 (1996).
  CAS PubMed Google Scholar
• Witzig, T. E. et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109, 1804–1810 (2007).
  Article CAS PubMed Google Scholar
• Jean, G. W. & Shah, S. R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28, 742–754 (2008).
  Article CAS PubMed Google Scholar
• Perez-Soler, R. & Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23, 5235–5246 (2005).
  Article PubMed Google Scholar
• Bianchini, D., Jayanth, A., Chua, Y. J. & Cunningham, D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin. Colorectal Cancer 7, 33–43 (2008).
  Article CAS PubMed Google Scholar
• Saif, M. W., Longo, W. L. & Israel, G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin. Colorectal Cancer 7, 144–148 (2008).
  Article CAS PubMed Google Scholar
• Bauer, K. A., Hammerman, S., Rapoport, B. & Lacouture, M. E. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clin. Colorectal Cancer 7, 309–314 (2008).
  Article PubMed Google Scholar
• Bernier, J. et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 19, 142–149 (2008).
  Article CAS PubMed Google Scholar
• Scope, A. et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25, 5390–5396 (2007).
  Article CAS PubMed Google Scholar
• Hudis, C. A. Trastuzumab — mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).
  Article CAS PubMed Google Scholar
• Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Rev. Cancer 7, 332–344 (2007).
  Article CAS Google Scholar
• Guglin, M., Cutro, R. & Mishkin, J. D. Trastuzumab-induced cardiomyopathy. J. Card. Fail. 14, 437–444 (2008).
  Article CAS PubMed Google Scholar
• Klein, P. M. & Dybdal, N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin. Oncol. 30, 49–53 (2003).
  Article CAS PubMed Google Scholar
• Perez, E. A. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin. Breast Cancer 8 (Suppl. 3), 114–120 (2008).
  Article Google Scholar
• Chien, K. R. Herceptin and the heart — a molecular modifier of cardiac failure. N. Engl. J. Med. 354, 789–790 (2006).
  Article CAS PubMed Google Scholar
• Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
  Article CAS PubMed Google Scholar
• Force, T. & Kerkela, R. Cardiotoxicity of the new cancer therapeutics — mechanisms of, and approaches to, the problem. Drug Discov. Today 13, 778–784 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, M. H., Kerkela, R. & Force, T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 117, 84–95 (2008).
  Article Google Scholar
• Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459–465 (2002).
  Article CAS PubMed Google Scholar
• Kuramochi, Y., Guo, X. & Sawyer, D. B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell Cardiol. 41, 228–235 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Grazette, L. P. et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44, 2231–2238 (2004).
  Article CAS PubMed Google Scholar
• Lemmens, K., Doggen, K. & Keulenaer, G. W. Neuregulin-1 and its potential role in the control of cardiac function. Heart Fail. Monit. 5, 119–124 (2008).
  CAS PubMed Google Scholar
• Clark, I. A. The advent of the cytokine storm. Immunol. Cell Biol. 85, 271–273 (2007).
  Article CAS PubMed Google Scholar
• Wing, M. Monoclonal antibody first dose cytokine release syndromes — mechanisms and prediction. J. Immunotoxicol. 5, 11–15 (2008).
  Article CAS PubMed Google Scholar
• Plevy, S. et al. A Phase I study of visilzumab, a humanised anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133, 1414–1422 (2007).
  Article CAS PubMed Google Scholar
• Wing, M. G., Waldmann, H., Isaacs, J., Compston, D. A. & Hale, G. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther. Immunol. 2, 183–190 (1995).
  CAS PubMed Google Scholar
• Wing, M. G. et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98, 2819–2826 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Winkler, U. et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94, 2217–2224 (1999).
  Article CAS PubMed Google Scholar
• Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006). A detailed description of the laboratory events and clinical course after administration of TGN1412 to healthy volunteers: the cytokine storm.
  Article CAS Google Scholar
• Kenter, M. J. & Cohen, A. F. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368, 1387–1391 (2006).
  Article CAS PubMed Google Scholar
• Expert Group on Phase One Clinical Trials (Chairman: Professor Gordon W.Duff) Expert Scientific Group on Phase One Clinical Trials: Final Report (The Stationery Office, Norwich, UK, 2006). Report of a UK Expert Group commenting on safety of Phase I studies in the light of the TGN1412 cytokine storm.
• Association of the British Pharmaceutical Industry (ABPI), BioIndustry Association (BIA).Early Stage Clinical Trial Taskforce — Joint ABPI/BIA Report. ABPI website [online], (2006).
• Muller, P. Y., Milton, M., Lloyd, P., Sims, J. & Brennan, F. R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr. Opin. Biotechnol. 20, 722–729 (2009).
  Article CAS PubMed Google Scholar
• Beyersdorf, N., Hanke, T., Kerkau, T. & Hunig, T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann. Rheum. Dis. 64 (Suppl. 4), iv91–iv95 (2005).
  CAS PubMed PubMed Central Google Scholar
• Beyersdorf, N. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445–455 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Hunig, T. & Dennehy, K. CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. 100, 21–28 (2005).
  Article PubMed CAS Google Scholar
• Muller, N. et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J. Clin. Invest. 118, 1405–1416 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Hunig, T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv. Immunol. 95, 111–148 (2007).
  Article PubMed CAS Google Scholar
• Schraven, B. & Kalinke, U. CD28 superagonists: what makes the difference in humans? Immunity 28, 591–595 (2008).
  Article CAS PubMed Google Scholar
• Liu, E. H., Siegel, R. M., Harlan, D. M. & O'Shea, J. J. T cell-directed therapies: lessons learned and future prospects. Nature Immunol. 8, 25–30 (2007).
  Article CAS Google Scholar
• Sharpe, A. H. & Abbas, A. K. T-cell costimulation-biology, therapeutic potential, and challenges. N. Engl. J. Med. 355, 973–975 (2006).
  Article CAS PubMed Google Scholar
• Dayan, C. M. & Wraith, D. C. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clin. Exp. Immunol. 151, 231–234 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• St Clair, E. W. The calm after the cytokine storm: lessons from the TGN1412 trial. J. Clin. Invest. 118, 1344–1347 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hanke, T. Lessons from TGN1412. Lancet 368, 1569–1570 (2006).
  Article PubMed Google Scholar
• Ohresser, M., Olive, D., Vanhove, B. & Watier, H. Risk in drug trials. Lancet 368, 2205–2206 (2006).
  Article PubMed Google Scholar
• Waibler, Z. et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 3, e1708 (2008). In vitro studies on human blood cell signalling with superagonist human CD28-specific mAbs.
  Article PubMed PubMed Central CAS Google Scholar
• Mehrishi, J. N., Szabo, M. & Bakacs, T. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials. Vaccine 25, 3517–3523 (2007).
  Article CAS PubMed Google Scholar
• Yokosuka, T. & Saito, T. Dynamic regulation of T-cell costimulation through TCR-CD28 microclusters. Immunol. Rev. 229, 27–40 (2009).
  Article CAS PubMed Google Scholar
• Buysmann, S. et al. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 87, 404–411 (1996).
  Article CAS PubMed Google Scholar
• Mourad, G. J. et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation 65, 632–641 (1998).
  Article CAS PubMed Google Scholar
• Hernandez-Caselles, T. et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J. Leukoc. Biol. 79, 46–58 (2006).
  Article CAS PubMed Google Scholar
• Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P. & Varki, A. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl Acad. Sci. USA 103, 7765–7770 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Isaacs, J. D. et al. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106, 427–433 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Avril, T., Attrill, H., Zhang, J., Raper, A. & Crocker, P. R. Negative regulation of leucocyte functions by CD33-related siglecs. Biochem. Soc. Trans. 34, 1024–1027 (2006).
  Article CAS PubMed Google Scholar
• Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nature Rev. Immunol. 7, 255–266 (2007).
  Article CAS Google Scholar
• Crocker, P. R. & Redelinghuys, P. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36, 1467–1471 (2008).
  Article CAS PubMed Google Scholar
• Gogishvili, T. et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4, e4643 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Perruche, S. et al. Lethal effect of CD3-specific antibody in mice deficient in TGF-β1 by uncontrolled flu-like syndrome. J. Immunol. 183, 953–961 (2009).
  Article CAS PubMed Google Scholar
• Muller, P. Y. & Brennan, F. R. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85, 247–258 (2009).
  Article CAS PubMed Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on strategies to identify and mitigate risks for first in human clinical trials with investigational medicinal products. Doc. Ref. EMEA/CHMP/SWP/28367/07. EMA website [online], (2007).
• European Medicines Agency. ICH topic M 3 (R2): non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (CPMP/ICH/286/95). EMA website [online], (2008).
• European Medicines Agency. ICH topic S 6: preclinical safety evaluation of biotechnology-derived pharmaceuticals. Note for guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals (CPMP/ICH/302/95). EMA website [online], (1998).
• Lappin, G. & Garner, R. C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4, 1499–1506 (2008).
  Article CAS PubMed Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP/2599/02. EMA website [online], (2004).
• Liedert, B., Bassus, S., Schneider, C. K., Kalinke, U. & Lower, J. Safety of phase I clinical trials with monoclonal antibodies in Germany — the regulatory requirements viewed in the aftermath of the TGN1412 disaster. Int. J. Clin. Pharmacol. Ther. 45, 1–9 (2007).
  Article CAS PubMed Google Scholar
• Wafelman, A. R. Commentary: symposium report — Development of safe protein therapeutics: pre-clinical, clinical and regulatory issues. Eur. J. Pharm. Sci. 34, 223–225 (2008).
  Article CAS PubMed Google Scholar
• Stebbings, R. et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179, 3325–3331 (2007).
  Article CAS PubMed Google Scholar
• Findlay, L. et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Methods 352, 1–12 (2010).References 208 and 209 describe in vitro studies with mAbs and human blood and cell cultures to study the propensity to cause a cytokine storm.
  Article CAS PubMed Google Scholar
• Willmann, J. K., van, B. N., Dinkelborg, L. M. & Gambhir, S. S. Molecular imaging in drug development. Nature Rev. Drug Discov. 7, 591–607 (2008).
  Article CAS Google Scholar
• Bullen, A. Microscopic imaging techniques for drug discovery. Nature Rev. Drug Discov. 7, 54–67 (2008).
  Article CAS Google Scholar